Octagon Capital Advisors LP: KYMERA THERAPEUTICS INC (KYMR): Quarterly 13F Position History
As of Q1 2026, Octagon Capital Advisors LP reported 425,000 shares of KYMERA THERAPEUTICS INC (KYMR), worth $35.4M and representing 3.9% of its 13F equity book. Quarter-over-quarter share count change: 110,000 (-20.6%) . The position first appeared in Q2 2021 and has been disclosed across 20 13F-HR filings in Pactolio's tracked window.
- 425,000Shares Held (Latest Filing)
- $35.4MReported Market Value (Latest Filing)
- 3.9%Portfolio Weight (% of 13F Equity Book)
- 110,000Quarter-over-Quarter Share Change
- -$6.2MQuarter-over-Quarter Value Change
- 535,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 20 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 425,000 | 110,000 | -20.6% | $35.4M | 3.9% | $83.3 |
| Q4 2025 | 535,000 | +175,000 | +48.6% | $41.6M | 5.2% | $77.8 |
| Q3 2025 | 360,000 | +94,000 | +35.3% | $20.4M | 3.2% | $56.6 |
| Q2 2025 | 266,000 | +266,000 | — | $11.6M | 2.5% | $43.6 |
| Q1 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2021 | 0 | 100,000 | -100.0% | $0 | 0.0% | — |
| Q2 2021 | 100,000 | — | — | $4.8M | 1.0% | $48.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Octagon Capital Advisors LP first disclose a KYMR position in 13F-HR filings?
Octagon Capital Advisors LP first reported KYMERA THERAPEUTICS INC (KYMR) on its 13F-HR filing for the period ending 2021-06-30 (Q2 2021). The position has appeared on 20 reported quarters within Pactolio's tracked window.
What was Octagon Capital Advisors LP's most recent quarter-over-quarter share-count change in KYMR?
Between Q4 2025 and Q1 2026, Octagon Capital Advisors LP reduced its KYMR position by 110,000 shares (-20.6%), leaving 425,000 shares at a market value of $35.4M.
Does the implied price-per-share represent Octagon Capital Advisors LP's cost basis in KYMR?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.